Flatiron Health Announces New Partnership in the UK
Expansion into UK marks company’s third international subsidiary.
Flatiron Health, an oncology-focused RWD technology company, has partnered with the Leeds Teaching Hospitals NHS Trust (LTHT), one of largest acute hospital trusts in Europe. The entry into the United Kingdom marks a major milestone in Flatiron’s expansion.
Flatiron International has subsidiaries already in Japan and Germany. Each partners with hospitals and health networks in RWD collaborations through Flatiron's local teams and infrastructure, ensuring that strict legal and regulatory requirements are met in all locations. The goal is to produce more top-quality oncology datasets for use by Flatiron’s hospital and health network partners in research collaborations and under license—with specific terms and conditions—to biopharma companies, to accelerate cancer research.
“Each Flatiron International partnership is designed to help local healthcare providers and partners generate and utilize high-quality RWD to advance oncology research and care,” said Nathan Hubbard, SVP, Flatiron’s head of corporate development and Flatiron International. He noted that the agreement was approved by the NHS Health Research Authority.
Reference: Flatiron Health Announces New Partnership in the UK, June 20, 2023.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
